普拉克索添加治疗帕金森病的疗效观察

Efficacy observation of Pramipexole add-on therapy in Parkinson's disease

目的观察添加普拉克索治疗帕金森病(PD)的疗效和安全性。方法 78例Hoehn-Yahr分级为Ⅱ～Ⅲ级的PD患者在接受左旋多巴达到剂量稳定≥30d的基础上随机分为3组。A组添加普拉克索0.125mg,每日2次,4周滴定至0.75mg/d,维持8周。B组添加普拉克索0.125mg,每日2次,6周滴定至1.5mg/d,维持6周。C组不添加普拉克索。治疗前后应用统一PD评定量表(UPDRS)评分并评估疗效,观察不良反应。结果与治疗前相比,治疗12周A组、B组的UPDRSⅡ、Ⅲ评分明显下降(均P<0.05);B组显效率(21例,80.8%)显著高于A组(12例,46.2%)(P<0.01)。3组均未发生严重不良反应。B组2例出现轻度头晕、恶心,未影响治疗。结论应用左旋多巴治疗的PD患者添加普拉克索可以有效缓解症状,改善生活质量;添加普拉克索1.5mg/d的疗效优于0.75mg/d。

Objective To observe the efficacy and safety of Pramipexole add-on therapy in Parkinson＇s disease（PD）.Methods 78 PD patients （Hoehn Yahr Scale Ⅱ～Ⅲ） who received levodopa with stable doses ≥30 d were randomly divided into 3 groups. A group：The started dose of Pramipexole add-on therapy was 0.125 mg twice a day,add to 0.75 mg/d at the 4th week,and keep this dosage for 8 weeks. B group：The started dose of Pramipexole add-on therapy was 0.125 mg twice a day,add to 1.5 mg/d at the 6th week,and keep this dosage for 6 weeks. C group：No receiving Pramipexole add-on therapy. The efficacy was measured according to the scores of Unified PD Rating Scale （UPDRS） pre and post Pramipexole add-on therapy. The adverse reactions was observed.Results After 12 weeks of Pramipexole add-on therapy,the scores of UPDRSⅡand UPDRS Ⅲ in A group and B group had obviously decreased compared with prior treatment （all P0.05）. Excellence rate in B group （21 cases,80.8%） was superior to A group （12 cases,46.2%） （P0.01）. There was no serious adverse reaction in each group. 2 cases in B group felt little dizziness and nausea,but did not affect treatment.Conclusion Appended Pramipexole in PD patients who received levodopa may release symptoms,improve life quality. The dose of 1.5 mg/d in Pramipexole add-on therapy will get better efficacy than 0.75 mg/d.